Gain Therapeutics (GANX) Exchange Rate Effect (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Exchange Rate Effect of $24589.0 for Q1 2026, down 77.55% year-over-year from $109535.0 in Q1 2025, and down 74.85% quarter-over-quarter from $97760.0 in Q4 2025.
Gain Therapeutics (GANX) Exchange Rate Effect (2020 - 2026) Analysis & Trends
Gain Therapeutics' Exchange Rate Effect history runs 7 years deep, the most recent figure standing at $24589.0 for Q1 2026.
- In Q1 2026, Exchange Rate Effect fell 77.55% year-over-year to $24589.0; the TTM figure through Mar 2026 stood at $389086.0 (up 1464.48% YoY), while the FY2025 annual figure was $474032.0, up 189.92% from the prior year.
- Exchange Rate Effect for Q1 2026 stood at $24589.0, down from $97760.0 in the prior quarter.
- The five-year high for Exchange Rate Effect was $483249.0 in Q4 2023, with the low at -$480592.0 in Q4 2024.
- The 5-year median for Exchange Rate Effect is $24589.0 (2026), against an average of $25650.6.
- The sharpest annual moves came in 2024 and 2025: Exchange Rate Effect plunged 1251.69% in 2024, then soared 1881.94% in 2025.
- Gain Therapeutics' Exchange Rate Effect stood at $226051.0 in 2022, then surged by 113.78% to $483249.0 in 2023, then tumbled by 199.45% to -$480592.0 in 2024, then soared by 120.34% to $97760.0 in 2025, then sank by 74.85% to $24589.0 in 2026.
- Business Quant data shows GANX's Exchange Rate Effect at $24589.0 in Q1 2026, $97760.0 in Q4 2025, and $6667.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -2.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.84 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -2.45 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -287,000.00 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.63 Mn |
| 10 | Gain Therapeutics | 85.12 Mn | 85.12 Mn | - | -141,631.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -141,631.00 |
| Jun 30, 2026 | -141,631.00 |
| Mar 31, 2026 | 24,589.00 |
| Mar 31, 2026 | 24,589.00 |
| Dec 31, 2025 | 97,760.00 |
| Dec 31, 2025 | 97,760.00 |
| Sep 30, 2025 | 6,667.00 |
| Sep 30, 2025 | 6,667.00 |
| Jun 30, 2025 | 260,070.00 |
| Jun 30, 2025 | 260,070.00 |
| Mar 31, 2025 | 109,535.00 |
| Mar 31, 2025 | 109,535.00 |
| Dec 31, 2024 | -480,592.00 |
| Dec 31, 2024 | -480,592.00 |
| Sep 30, 2024 | 382,805.00 |
| Sep 30, 2024 | 382,805.00 |
| Jun 30, 2024 | 13,122.00 |
| Jun 30, 2024 | 13,122.00 |
| Mar 31, 2024 | -442,503.00 |
| Mar 31, 2024 | -442,503.00 |